The potential public health value of vaccines against nontyphoidal salmonella (NTS) infections is becoming an increasingly important question, with several candidate vaccines now in development against invasive NTS disease (iNTS). However, the health
and economic benefit of an iNTS vaccine alone, or in combination with other Salmonella vaccines, and the respective product development pathways have not been fully considered. These are critical aspects to assess as WHO and other stakeholders embark
on determining how best to support and accelerate investment in and development of iNTScontaining vaccines.
Under a recently awarded 3-year grant by the Wellcome Trust, IVI, WHO and other global partners are collaborating to develop a Full Value of Vaccines Assessment (FVVA) to understand both the general and specific value of investment in
an iNTS vaccine (or vaccines). The intent is to define the pathway for the development of safe and efficacious iNTS vaccine/s, including licensure, policy recommendations from SAGE, WHO prequalification, Gavi financing, UNICEF purchasing and national
technical advisory group recommendations for use.
